Xencor, Inc. (XNCR) is a publicly traded Healthcare sector company. As of May 21, 2026, XNCR trades at $11.36 with a market cap of $820.01M and a P/E ratio of -4.86. XNCR moved +8.79% today. Year to date, XNCR is -20.67%; over the trailing twelve months it is +39.07%. Its 52-week range spans $6.92 to $27.24. Analyst consensus is strong buy with an average price target of $26.00. Rallies surfaces XNCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Xencor’s XmAb942 Phase 1 Yields >99% TL1A Inhibition, Phase 2b on Track: Xencor’s Phase 1 XmAb942 trial showed >99% TL1A inhibition in induction and >90% in maintenance with a 12-week subcutaneous dose and no serious adverse reactions. Phase 2b XENITH-UC’s ~220 patients enroll on schedule for a year-end 2026 interim analysis and H2 2027 primary results, while first-in-human XmAb412 begins Q3 2026.
| Metric | Value |
|---|---|
| Price | $11.36 |
| Market Cap | $820.01M |
| P/E Ratio | -4.86 |
| EPS | $-2.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.24 |
| 52-Week Low | $6.92 |
| Volume | 449 |
| Avg Volume | 0 |
| Revenue (TTM) | $97.36M |
| Net Income | $-172.42M |
| Gross Margin | 0.00% |
12 analysts cover XNCR: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $26.00.